ストックスクリーナーアプリを入手
0.57
2.40%
-0.014
前日終値:
$0.584
開ける：
$0.58
24時間の取引高:
6,021
Relative Volume:
0.02
時価総額：
$55.66M
収益：
$1.29M
当期純損益:
$-29.87M
株価収益率:
-1.5833
EPS:
-0.36
ネットキャッシュフロー:
$-14.70M
1週間 パフォーマンス:
-6.17%
1か月 パフォーマンス:
-15.25%
6か月 パフォーマンス:
-0.02%
1年 パフォーマンス:
-52.10%
1日の値動き範囲:
$0.566
$0.59
1週間の範囲:
$0.566
$0.625
52週間の値動き範囲:
$0.4301
$1.23
VolitionRX Ltd Stock (VNRX) Company Profile
名前
VolitionRX Ltd
セクター
電話
646 650 1351
住所
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
VNRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.57 | 55.66M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
580.14 | 222.07B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
213.41 | 153.63B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.84 | 42.00B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
463.60 | 38.47B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
204.14 | 36.80B | 15.32B | 1.41B | 1.96B | 7.62 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-02-01 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 開始されました | Maxim Group | Buy |
| 2018-05-14 | 繰り返されました | The Benchmark Company | Buy |
| 2016-09-07 | 繰り返されました | Rodman & Renshaw | Buy |
| 2016-02-01 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
VolitionRX Ltd (VNRX) 最新ニュース
Game-Changing Sepsis Detection: 971-Patient Study Validates Revolutionary Blood Test - StockTitan
D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRx reports expanded global reach in 2024 - Investing.com India
VolitionRx's Nu.Q® Vet Cancer Test Hits Major Milestone: 110,000+ Tests Sold Across 20 Countries - StockTitan
VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World
VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock By Investing.com - Investing.com Nigeria
Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Australia
Volitionrx director Innes buys $99,999 in common stock - Investing.com India
VolitionRx chief scientific officer Micallef acquires $24,999 in stock By Investing.com - Investing.com Australia
VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock - Investing.com
SEC Form 424B5 filed by VolitionRX Limited - Quantisnow
Form 424B5 VOLITIONRX LTD - StreetInsider.com
VolitionRx announces pricing of up to $1.9M registered direct offering - MSN
VolitionRx announces $1.9 million stock sale By Investing.com - Investing.com Australia
VolitionRx Secures $1.9M Financing with Insider Backing, Includes Strategic Warrant Package - StockTitan
VNRX: VolitionRx Reports 3Q 2024 results. Over 110,000 Nu.Q Canine Cancer tests have been sold. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR & Nu.Q NETs. - Zacks Small Cap Research
VolitionRx: Big EU Trials On Deck - Investing.com
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Benchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX) - MarketBeat
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
VolitionRx Limited (AMEX:VNRX) Q3 2024 Earnings Call Transcript - Insider Monkey
VolitionRX: Q3 Earnings Snapshot - New Haven Register
VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
VolitionRx Posts Strong Q3 Growth and Strategic Advances - TipRanks
Lagoda Investment Management's Strategic Acquisition in Volition - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in VolitionRX Ltd - GuruFocus.com
VolitionRX Ltd Reports Q3 Revenue of $475,000, Missing Estimates of $0.65 Million - GuruFocus.com
VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to L - GuruFocus.com
VolitionRx (VNRX) Sets Q3 2024 Earnings Call: Key Executives to Present Financial Results | VNRX Stock News - StockTitan
Volition Appoints Timothy I. Still as Chairman – Company Announcement - Financial Times
VolitionRx (NYSE:VNRX) Now Covered by StockNews.com - Defense World
Abionic’s test enters increasingly competitive sepsis fray - BioWorld Online
VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com - Defense World
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar - Quantisnow
VolitionRx adds Dr. Ethel Rubin to its board By Investing.com - Investing.com South Africa
VolitionRx adds Dr. Ethel Rubin to its board - Investing.com India
Volition Appoints Dr. Ethel Rubin as an Independent Director - Quantisnow
VolitionRx announces executive employment updates - Investing.com India
Agency News | ⚡Tamil Nadu’s Veterinary Varsity Directed by High Court To Consider Transgender Student’s Application - LatestLY
Madras HC directs TN veterinary varsity to not reject transgender's application over identity - Hindustan Times
Madras High Court Orders TN Veterinary University to Accept Transgender Candidate's Application - Law Trend
Don't reject transgender's application over identity HC tells TN veterinary varsity - The Week
Madras High Court Upholds Transgender Rights for Veterinary Course Admissions - Devdiscourse
Volato Facing Class-action WARN Act Lawsuit - Aviation International News
VolitionRX Ltd (VNRX) 財務データ
収益
当期純利益
現金流量
EPS
2.58%
大文字化:
|
ボリューム (24 時間):